89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer

PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective

(2017) Jun Wang et al.   Journal of Hematology & Oncology

Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy

(2017) Thomas J Gniadek et al.   MODERN PATHOLOGY

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma

(2016) Adil I. Daud et al.   JOURNAL OF CLINICAL INVESTIGATION

Molecular Imaging of Immunotherapy Targets in Cancer

(2016) E. B. Ehlerding et al.   JOURNAL OF NUCLEAR MEDICINE

Preclinical Pharmacokinetics and Biodistribution Studies of 89 Zr-Labeled Pembrolizumab

(2016) Christopher G. England et al.   JOURNAL OF NUCLEAR MEDICINE

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer

(2016) Congqi Dai et al.   Oncotarget

PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells

(2016) Yanan Guo et al.   Oncotarget

CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody

(2016) Reinier Hernandez et al.   Theranostics

High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers

(2016) Michael Hettich et al.   Theranostics

Tumor infiltrating lymphocytes in lung cancer: a new prognostic parameter

(2016) Kobe Reynders et al.   Journal of Thoracic Disease

Predicting the response to anti-PD1 therapy in metastatic melanoma

(2016) Lucie Heinzerling et al.   Translational Cancer Research

Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes

(2015) Arutselvan Natarajan et al.   BIOCONJUGATE CHEMISTRY

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2015) Scott N. Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types

(2015) April K. Salama et al.   OncoTargets and Therapy

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies

(2014) G. K. Philips et al.   INTERNATIONAL IMMUNOLOGY

Generation of improved humanized mouse models for human infectious diseases

(2014) Michael A. Brehm et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Dysfunction of Lacrimal and Salivary Glands in Sjögren's Syndrome: Nonimmunologic Injury in Preinflammatory Phase and Mouse Model

(2011) Toshiharu Hayashi   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology